Organigram Processing
About Organigram Processing
Organigram's processing division manufactures cannabis derivatives including vapes, edibles, and concentrates, leveraging BAT's strategic investment for next-generation product innovation.
Key Facts
- 1British American Tobacco invested CAD $221 million for a 19.9% stake and a product development partnership
- 2Achieved leading market share in Canadian edibles and vape categories with brands like SHRED
Latest News
Organigram Holdings Near 52-Week Low as Cannabis Sector Struggles
OGI trades at $0.87, just 2% above its 52-week low of $0.85, reflecting broader cannabis industry challenges and company-specific pressures.
OGI Stock Tests Canadian Cannabis Profit Viability Amid Sector Shakeout
Organigram Holdings faces critical profitability challenges as Canada's cannabis market consolidates around sustainable operators.
Organigram Outlines Strategic Vision as Cannabis Volatility Persists
OGI management details operational priorities and market positioning strategy while cannabis sector faces continued price pressure and uncertainty.
Frequently Asked Questions
What is Organigram's relationship with BAT?
British American Tobacco invested in Organigram and established a Centre of Excellence collaboration to develop next-generation cannabis delivery and extraction technologies.
What Cannabis 2.0 products does Organigram make?
Organigram produces vapes, gummies, chocolates, concentrates, and infused pre-rolls under brands including SHRED, Edison, and Monjour.
Products
- Cannabis Vape Products
- Edibles and Gummies
- Cannabis Concentrates
Specialties
Company Details
- Type
- Extraction
- Location
- Moncton, NB, Canada
- Founded
- 2013
- Publicly Traded
- Yes
- Ticker
- NASDAQ:OGI